Belviq XR Approved for Chronic Weight Management
Eisai and Arena announced that the Food and Drug Administration (FDA) has approved Belviq XR (lorcaserin HCl extended-release tablets).
Belviq XR, a CIV controlled substance, is indicated for use with a reduced-calorie diet and increased physical activity for chronic weight management in adults who have a body mass index (BMI) of ≥30kg/m2 (obese) or BMI of ≥27kg/m2 (overweight) with at least one weight-related medical condition (eg, high blood pressure, high cholesterol, type 2 diabetes).
Data from two Phase 1 registrational clinical trials in healthy adult participants supported the
Both Belviq and Belviq XR are serotonin 2C receptor agonists that are believed to decrease food consumption and promote satiety by selectively activating 5-HT2C receptors on anorexigenic pro-opiomelanocortin neurons located in the hypothalamus.
Belviq XR will be available in 20mg strength extended-release tablets in 30-count bottles. It is anticipated to launch in the Fall of 2016. Belviq is already available as 10mg strength tablets in 60-count bottles.
For more information call (888) 274-2378 or visit BelviqXR.com.